15 / 23
Page 61
allied
academies
J Med Oncl Ther 2017 | Volume 2 Issue 4
Oncology and Biomarkers Summit
November 27-28, 2017 | Atlanta, USA
Annual Congress on
R
outine disease monitoring of ovarian cancer patients
is generally recommended by gynecologic oncologists
for women from high-risk families and for ovarian cancer
patients during after the completion of primary surgery
and first-line chemotherapeutic treatments. The recurrence
is determined by measuring the level of serum CA125,
one of the most extensively used tumor biomarkers in
standard clinical practice for disease surveillance. Numerous
studies have shown the role of tumor autoantibodies as
biomarkers for ovarian cancer diagnosis and its recurrence.
These autoantibodies to tumor associated antigens (TAAs)
arise due to the generation of humoral immune response
before evidence of clinical symptoms in cancer patients.
Previously, we showed that 3 biomarker panel predicted
ovarian cancer recurrence at a median lead time of 9.07
months with 94.7% sensitivity, 86.7% specificity and 93.3%
accuracy, in a cohort of ovarian cancer patients where
normalization of CA125 had occurred after the surgery and
completion of chemotherapy. One of those biomarkers was
a peptide epitope from a known paraneoplastic antigen,
HARS. Paraneoplastic antigens can elicit a humoral immune
response in cancer patients as these antigens are expressed
in the cells of nervous system and tumor. The appearance of
these onconeural antibodies in ovarian cancer patients leads
to the development of various neurological disorders called
paraneoplastic syndromes, particularly dermatomyositis
or polymyositis but can precede the occurrence of
dermatomyositis or polymyositis. Although the clinical
implication of these onconeural antibodies as biomarkers for
early diagnosis of ovarian cancer has been reported in many
case studies, the usefulness of these antibodies has yet to
be evaluated in monitoring disease status in ovarian cancer
patients after cytoreductive surgery and chemotherapy
treatments. In the present study we evaluated the role of a
panel of 3 recombinant paraneoplastic antigens, HARS, CDR2
and Ro52 in combination with 3 of our previous biomarkers
in predicting recurrence in new and independent cohort
of ovarian cancer patient population in which most of the
patients had no elevation in CA125 level months before their
clinical recurrence. Our results indicate that autoantibodies
to HARS, Ro52 and CDR2 and 5H6 antigens predicted
ovarian cancer recurrence 5.03 months before the clinical
or symptomatic relapse in 21 ovarian cancer patients with
a sensitivity of 90.5% when CA125 levels were below the
standard cutoff (35 U/ml). We have expanded the biomarker
panel and test a larger sample size for the early detection
of ovarian cancer using a newly developed ELISA protocol
employing a large number of sera from patients and women
with benign gynecological diseases.
e:
tainskym@med.wayne.eduParaneoplastic antigens as biomarkers for early detection and prediction of recurrence of ovarian cancer
Michael A Tainsky
Wayne State University School of Medicine, USA